FAS and Splenomegaly: Overall, leniolisib induced a dose-related reduction in canonical clinical features of ALPS-FAS in the murine model, including lymphadenopathy, splenomegaly, and elevated CD4−/CD8− DNTs in blood, spleen, and lymph nodes, and thus reduced the overall disease burden.